These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8470875)

  • 21. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
    Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does the management of bladder perforation during transurethral resection of superficial bladder tumors predispose to extravesical tumor recurrence?
    Skolarikos A; Chrisofos M; Ferakis N; Papatsoris A; Dellis A; Deliveliotis C
    J Urol; 2005 Jun; 173(6):1908-11. PubMed ID: 15879773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
    Raman JD; Sosa RE; Vaughan ED; Scherr DS
    Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Significance of random biopsies of healthy mucosa in superficial bladder tumor].
    Fernández Gómez JM; Rodríguez Martínez JJ; Escaf Barmadah S; Pérez García J; García J; Casasola Chamorro J
    Arch Esp Urol; 2000 Nov; 53(9):785-97. PubMed ID: 11196385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conservative management of low risk superficial bladder tumors.
    Pruthi RS; Baldwin N; Bhalani V; Wallen EM
    J Urol; 2008 Jan; 179(1):87-90; discussion 90. PubMed ID: 17997444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A clinical study of recurrence and progression of grade 3 superficial bladder tumor].
    Ikegami S; Tsuji A; Suzuki S; Sumitomo M; Kimura F; Asano T; Nakajima F; Hayakawa M
    Hinyokika Kiyo; 1999 May; 45(5):325-9. PubMed ID: 10410314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy.
    Hurle R; Losa A; Ranieri A; Graziotti P; Lembo A
    J Urol; 1996 Nov; 156(5):1602-5. PubMed ID: 8863547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Course of superficial carcinoma of bladder (Ta-T1). Apropos of 171 cases].
    Novak R
    J Urol (Paris); 1987; 93(1):21-4. PubMed ID: 3559256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effect of prophylactic intravesical instillation of BCG for superficial bladder cancer].
    Segawa N; Inamoto T; Nomi H; Ibuki N; Azuma H; Katsuoka Y
    Hinyokika Kiyo; 2009 Apr; 55(4):175-80. PubMed ID: 19462820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
    BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Superficial bladder cancer: decreasing the risk of recurrence.
    Grossman HB
    Oncology (Williston Park); 1996 Nov; 10(11):1617-24; discussion 1624, 1627-8. PubMed ID: 8953583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K; Chihara Y; Kondo H; Hirao Y
    Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A re-staging transurethral resection predicts early progression of superficial bladder cancer.
    Herr HW; Donat SM
    BJU Int; 2006 Jun; 97(6):1194-8. PubMed ID: 16566813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups.
    Millán-Rodríguez F; Chéchile-Toniolo G; Salvador-Bayarri J; Huguet-Pérez J; Vicente-Rodríguez J
    J Urol; 2000 Oct; 164(4):1183-7. PubMed ID: 10992362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Superficial transitional cell carcinoma of the ureteral orifice: higher risk of developing subsequent upper urinary tract tumors.
    Chou EC; Lin AT; Chen KK; Chang LS
    Int J Urol; 2006 Jun; 13(6):682-5. PubMed ID: 16834642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.